EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
EGFR-TKI
Osimertinib
Re-administration
T790M loss
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
07
08
2022
accepted:
05
09
2022
pubmed:
25
9
2022
medline:
16
11
2022
entrez:
24
9
2022
Statut:
ppublish
Résumé
Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration efficacy may vary between patients with T790M loss and those with T790M persistent with re-biopsy after osimertinib treatment. Patients who received EGFR-TKI re-administration (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) after osimertinib failure were identified from our database. T790M mutation status before EGFR-TKI re-administration was analyzed via repeat biopsy. We retrospectively evaluated the efficacy of EGFR-TKI re-administration, especially differences according to the T790M mutation status, via repeat biopsy. Until June 2020, 28 patients received EGFR-TKI re-administration and 17 underwent repeat biopsy after osimertinib failure. Patients were divided into three groups, including the T790M loss group, where active mutation persisted and T790M was lost (13/17); T790M remaining group, where both the active mutation and T790M persisted (3/17); and active mutation loss group where both the active mutation and T790M were lost (1/17). The overall response rate (ORR) of EGFR-TKI re-administration in the T790M loss group was 31% and the disease control rate (DCR) was 54%, which were higher than the ORR of 21% and DCR of 43% in the entire patient population. ORR and DCR of the not re-biopsy group were low (9% and 27%, respectively). The therapeutic effect of EGFR-TKI re-administration in patients with T790M-positive NSCLC after osimertinib failure is limited. EGFR-TKI re-administration may be considered in cases of T790M loss after repeat biopsy.
Identifiants
pubmed: 36152107
doi: 10.1007/s10637-022-01301-y
pii: 10.1007/s10637-022-01301-y
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
osimertinib
3C06JJ0Z2O
Protein Kinase Inhibitors
0
Aniline Compounds
0
EGFR protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1342-1349Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sève P, Reiman T, Dumontet C (2010) The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136–143. https://doi.org/10.1016/j.lungcan.2009.09.007
doi: 10.1016/j.lungcan.2009.09.007
pubmed: 19828208
Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. New Engl J Medicine 350:2129–2139. https://doi.org/10.1056/nejmoa040938
doi: 10.1056/nejmoa040938
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. New Engl J Medicine 362:2380–2388. https://doi.org/10.1056/nejmoa0909530
doi: 10.1056/nejmoa0909530
Wu Y-L, Zhou C, Hu C-P et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222. https://doi.org/10.1016/s1470-2045(13)70604-1
doi: 10.1016/s1470-2045(13)70604-1
pubmed: 24439929
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246. https://doi.org/10.1016/s1470-2045(11)70393-x
doi: 10.1016/s1470-2045(11)70393-x
pubmed: 22285168
Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/jco.2012.44.2806
doi: 10.1200/jco.2012.44.2806
pubmed: 23816960
Mitsudomi T, Morita S, Yatabe Y et al (2009) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128. https://doi.org/10.1016/s1470-2045(09)70364-x
doi: 10.1016/s1470-2045(09)70364-x
pubmed: 20022809
Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. https://doi.org/10.1126/scitranslmed.3002003
Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res 19:2240–2247. https://doi.org/10.1158/1078-0432.ccr-12-2246
doi: 10.1158/1078-0432.ccr-12-2246
pubmed: 23470965
pmcid: 3630270
Cross DAE, Ashton SE, Ghiorghiu S et al (2014) AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov 4:1046–1061. https://doi.org/10.1158/2159-8290.cd-14-0337
doi: 10.1158/2159-8290.cd-14-0337
pubmed: 24893891
pmcid: 4315625
Ballard P, Yates JWT, Yang Z et al (2016) Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 22:5130–5140. https://doi.org/10.1158/1078-0432.ccr-16-0399
doi: 10.1158/1078-0432.ccr-16-0399
pubmed: 27435396
Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M–Positive Lung Cancer. New Engl J Medicine 376:629–640. https://doi.org/10.1056/nejmoa1612674
doi: 10.1056/nejmoa1612674
Jänne PA, Yang JC-H, Kim D-W et al (2015) AZD9291 in EGFR Inhibitor-Resistant Non–Small-Cell Lung Cancer. New Engl J Medicine 372:1689–1699. https://doi.org/10.1056/nejmoa1411817
doi: 10.1056/nejmoa1411817
Inoue A, Yoshida K, Morita S et al (2016) Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol 46:462–467. https://doi.org/10.1093/jjco/hyw014
doi: 10.1093/jjco/hyw014
pubmed: 26977054
pmcid: 4874470
Leonetti A, Sharma S, Minari R et al (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Brit J Cancer 121:725–737. https://doi.org/10.1038/s41416-019-0573-8
doi: 10.1038/s41416-019-0573-8
pubmed: 31564718
pmcid: 6889286
Kohsaka S, Petronczki M, Solca F, Maemondo M (2019) Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol 15:637–652. https://doi.org/10.2217/fon-2018-0736
doi: 10.2217/fon-2018-0736
pubmed: 30404555
Group: O behalf of Ngse, Marino P, Touzani R et al (2018) Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet 26:314–323. https://doi.org/10.1038/s41431-017-0081-3
Papadimitrakopoulou VA, Wu Y-L, Han J-Y et al (2018) LBA51 analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol 29:viii741. https://doi.org/10.1093/annonc/mdy424.064
Oxnard GR, Hu Y, Mileham KF et al (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–Positive Lung cancer and acquired resistance to osimertinib. Jama Oncol 4:1527. https://doi.org/10.1001/jamaoncol.2018.2969
doi: 10.1001/jamaoncol.2018.2969
pubmed: 30073261
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244
Song Y, Wu Y-L, Cao L-J et al (2019) Efficacy and safety of gefitinib as third-line treatmentt in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. Am J Clin Oncol 42:432–439. https://doi.org/10.1097/coc.0000000000000538
doi: 10.1097/coc.0000000000000538
pubmed: 30950859
pmcid: 6493697
Becker A, Crombag L, Heideman DAM et al (2011) Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 47:2603–2606. https://doi.org/10.1016/j.ejca.2011.06.046
doi: 10.1016/j.ejca.2011.06.046
pubmed: 21784628
Oda N, Hotta K, Ninomiya K et al (2018) A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemoth Pharm 82:1031–1038. https://doi.org/10.1007/s00280-018-3694-5
doi: 10.1007/s00280-018-3694-5
Ichihara E, Hotta K, Ninomiya K et al (2019) Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer 132:54–58. https://doi.org/10.1016/j.lungcan.2019.02.021
doi: 10.1016/j.lungcan.2019.02.021
pubmed: 31097094
Ercan D, Choi HG, Yun C-H et al (2015) EGFR mutations and resistance to irreversible pyrimidine-based EGFRinhibitors. Clin Cancer Res 21:3913–3923. https://doi.org/10.1158/1078-0432.ccr-14-2789
doi: 10.1158/1078-0432.ccr-14-2789
pubmed: 25948633
pmcid: 4791951
Fassunke J, Müller F, Keul M et al (2018) Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun 9:4655. https://doi.org/10.1038/s41467-018-07078-0
doi: 10.1038/s41467-018-07078-0
pubmed: 30405134
pmcid: 6220297
Le X, Puri S, Negrao MV et al (2018) Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clin Cancer Res 24:clincanres.1542.2018. https://doi.org/10.1158/1078-0432.ccr-18-1542
Rotow JK, Costa DB, Paweletz CP et al (2020) Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). J Clin Oncol 38:9507–9507. https://doi.org/10.1200/jco.2020.38.15_suppl.9507
doi: 10.1200/jco.2020.38.15_suppl.9507
Arulananda S, Do H, Musafer A et al (2017) Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol 12:1728–1732. https://doi.org/10.1016/j.jtho.2017.08.006
doi: 10.1016/j.jtho.2017.08.006
pubmed: 28843359
Wang Z, Yang J-J, Huang J et al (2017) Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation egfr tkis and shifts allelic configuration at resistance. J Thorac Oncol 12:1723–1727. https://doi.org/10.1016/j.jtho.2017.06.017
doi: 10.1016/j.jtho.2017.06.017
pubmed: 28662863
Ariyasu R, Uchibori K, Sasaki T et al (2021) Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. Cancer Sci 112:2371–2380. https://doi.org/10.1111/cas.14879
doi: 10.1111/cas.14879
pubmed: 33686722
pmcid: 8177776
Low S-K, Ariyasu R, Uchibori K et al (2022) Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using oncomine precision assay with genexus tm integrated sequencer Transl Lung Cancer Res 0:0–0. https://doi.org/10.21037/tlcr-21-981